Abstract
Summary: Although Brightline-1 was headlined as a “negative trial,” brigimadlin showed clear biological activity, with the median PFS of 8.4 months, objective response rate of 22.3%, and translational evidence of p53 reactivation. Its failure largely reflects flawed control-arm assumptions, as doxorubicin outperformed retrospective expectations and established a new prospective benchmark in dedifferentiated liposarcoma. See related article by Schöffski et al., p. 4538